ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. Specialising in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies - ICON has the expertise to conduct clinical trials and development projects locally and globally. ICON provides development services on a stand-alone basis or as part of an integrated 'full service' solution.
ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and medical devices to market faster.
ICON offers design, simulation and execution of adaptive clinical trials. We are the only CRO that offers the knowledge, software, systems and global footprint to make global adaptive trials a reality. ICON has:
Clients also have access to the ICON Adaptive Trial Innovation Centre, a group of world-leading experts in adaptive design and execution that provide leadership in these key areas:
ICON specialises in the strategy and delivery of early-phase clinical development services to enable informed, timely decision-making for our clients. With expertise in early phase clinical research, bioanalytical, PK/PD modelling and simulation, and the full range of supporting services, we incorporate scientific excellence and product development strategy in all that we do. Our multi-disciplinary experts have the experience to address the most demanding drug development challenges with an unyielding focus on completing projects on time, on budget and with the quality that will withstand the most vigorous scrutiny.
Key services include:
ICON's customised services can be deployed as stand-alone or part of an integrated full-service solution to support global and locally managed projects.
ICON specialises in the planning, management, execution and analysis of Phase II-III clinical trials, ranging from small studies to complex, multinational projects.
ICON's commercialisation and outcomes practices provide insights to clients on strategies and execution for long-term value through customised engagements that fit the compound, the company and the market, maximising products' success and their benefits to patients' health. Speciality practices directed toward product commercialisation include: peri-approval and observational research; pricing and market access, health economics; patient reported outcomes; epidemiology; electronic clinical outcomes assessment; language services; and medical device and diagnostic research services.
ICON's dedicated medical device team understands the unique requirements of medical devices and diagnostics. Our medical device experts provide strategic support and tactical solutions for traditional devices, in vitro diagnostics, and software devices. Services include: